Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trialYan Zhao, Bo Chen, Jingyi Li et al.|Chinese Medical Journal|2023Cited by 40
Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis of a Randomized, Double-Blind Phase III StudyYan Zhao, Liming Wu, Qianjin Lu et al.|International Journal of Dermatology and Venereology|2022Cited by 4